Home » Stocks » Aimmune Therapeutics

Aimmune Therapeutics, Inc. (AIMT)

Stock Price: $13.99 USD -0.37 (-2.58%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $14.10 +0.11 (0.79%) Aug 13, 7:52 PM

Stock Price Chart

Key Info

Market Cap 915.65M
Revenue (ttm) 575,000
Net Income (ttm) -287.03M
Shares Out 65.45M
EPS (ttm) -4.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $13.99
Previous Close $14.36
Change ($) -0.37
Change (%) -2.58%
Day's Open 14.23
Day's Range 13.96 - 14.63
Day's Volume 642,976
52-Week Range 10.09 - 37.00

More Stats

Market Cap 915.65M
Enterprise Value 744.88M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 65.45M
Float 42.91M
EPS (basic) -4.49
EPS (diluted) -4.49
FCF / Share -3.60
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 18.96M
Short Ratio 18.30
Short % of Float 40.56%
Beta 0.84
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1,592.43
PB Ratio 5.01
Revenue 575,000
Operating Income -282.86M
Net Income -287.03M
Free Cash Flow -234.33M
Net Cash 170.77M
Net Cash / Share 2.61
Gross Margin n/a
Operating Margin -49,193.39%
Profit Margin -49,918.10%
FCF Margin -40,752.52%
ROA -53.24%
ROE -149.17%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (12)

Buy 6
Overweight 1
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$35.18*
(151.47% upside)
Low
14.0
Current: $13.99
High
66.0
Target: 35.18
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue-------
Operating Income-250-215-133-81.53-36.00-11.13-4.76
Net Income-248-211-131-80.82-35.82-11.12-4.83
Shares Outstanding62.5657.4050.4042.7519.042.932.93
Earnings Per Share-3.97-3.67-2.61-1.89-1.88-3.80-1.65
Operating Cash Flow-195-169-99.61-56.61-35.69-9.78-4.36
Capital Expenditures-8.05-9.42-6.43-7.67-1.71-0.06-0.07
Free Cash Flow-203-179-106-64.28-37.40-9.83-4.43
Cash & Equivalents1443041822491922.3111.95
Total Debt53.81------
Net Cash / Debt89.703041822491922.3111.95
Assets2043402072992122.5312.16
Liabilities10040.6129.1312.826.111.860.52
Book Value1042991782862060.6711.64
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aimmune Therapeutics, Inc.
Country United States
Employees 339
CEO Jayson Donald Alexander Dallas

Stock Information

Ticker Symbol AIMT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AIMT
IPO Date August 6, 2015

Description

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.